JMP Securities Downgrades Dynavax Technologies (DVAX) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Wall St futures gain as AI, consulting stocks offset bond-market jitters
- Oil prices rise 2% as China suspends fuel exports
- Elevated equity positioning, leverage could challenge stocks in Q4: JPMorgan
- Accenture shares jump on earnings beat and upbeat guidance
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
StreetInsider.com Pre-Open Movers 6/10: (STEL) (CSIQ) (SUPN) Higher; (DVAX) (ROVI) (EAC) Lower (more...)
June 10, 2013 9:31 AM EDTDynavax Technologies Corporation (NASDAQ: DVAX) 29.1% LOWER; reported that it recently concluded a meeting with FDA regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine. The meeting followed recommendations expressed in November 2012 by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) regarding the size of Dynavax's safety database. The meeting with FDA resulted in the following messages: * The safety database does indeed need additional subjects; * VRBPAC's strong endorsement of HEPLISAV's demonstrated immunogenicity was acknowledged; * Analyzing the benefit/risk of HEPLISAV's use in discrete patient populations did... More
FDA Requests More Info from Dynavax (DVAX) for HEPLISAV BLA
June 10, 2013 6:24 AM EDTDynavax Technologies Corporation (NASDAQ: DVAX) reported that it recently concluded a meeting with the U.S. Food and Drug Administration (FDA or Agency) regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine. The meeting followed recommendations expressed in November 2012 by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) regarding the size of Dynavax's... More
